Interleukin-1 (Interleukin 1)

A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.

Also Known As:

Networked: 9454 relevant articles (309 outcomes, 1050 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Iwakura, Yoichiro: 63 articles (12/2015 - 02/2002)
2.	Dinarello, Charles A: 51 articles (12/2015 - 01/2002)
3.	Rothwell, Nancy J: 37 articles (12/2015 - 05/2002)
4.	Apte, Ron N: 23 articles (05/2014 - 08/2002)
5.	Joosten, Leo A B: 21 articles (01/2015 - 06/2003)
6.	Voronov, Elena: 21 articles (04/2014 - 08/2002)
7.	Allan, Stuart M: 20 articles (12/2015 - 10/2003)
8.	Abbate, Antonio: 20 articles (02/2015 - 10/2002)
9.	Goldbach-Mansky, Raphaela: 18 articles (12/2015 - 12/2002)
10.	Gabay, Cem: 18 articles (01/2015 - 02/2002)

Related Diseases

1.	Inflammation 07/01/2003 - "Inhibitors of iNOS or IL-1 receptor may be beneficial for controlling lacrimal gland inflammation." 09/01/1995 - "These data suggest that IL-1 is a mediator of the inflammation resulting from active immunization with MBP, and that inhibitors of IL-1 may prove beneficial for the treatment of autoimmune or inflammatory diseases of the central nervous system." 08/01/2013 - "pylori-induced gastric inflammation and DNA methylation using IL-1 receptor type 1 knockout (IL-1R1(-/-)) mice, and compared the therapeutic efficacy of antimicrobial therapy with IL-1 receptor antagonist (IL-1ra). " 06/01/2004 - "These observations suggest that IL-1 is effective for evaluating in detail the state of subgingival inflammation." 07/01/1994 - "Administration of exogenous interleukin-1 receptor antagonist (IL-1ra) is effective in reducing the severity of disease in animal models of acute inflammation. "
2.	Rheumatoid Arthritis 07/01/2014 - "Interleukin-1 inhibition causes a greater improvement in endothelial, coronary aortic function in addition to left ventricular myocardial deformation and twisting in rheumatoid arthritis patients with CAD than in those without. " 11/01/1999 - "In contrast, blockade of IL-1 in rheumatoid arthritis patients, by an IL-1 receptor antagonist, was only moderately effective in suppressing inflammatory symptoms but appeared to reduce the rate of progression of joint destruction. " 05/01/2004 - "New interleukin-1 inhibitors with a potential for increased efficacy, such as interleukin-1trap, have been manufactured and are now being tested in rheumatoid arthritis. " 04/01/2001 - "The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis." 07/01/1996 - "To preliminarily evaluate the safety and efficacy of different dose levels and dosing frequencies of recombinant human interleukin-1 receptor antagonist (rHuIL-1Ra) in the treatment of patients with rheumatoid arthritis (RA). "
3.	Infection 12/01/2010 - "Furthermore, mice intranasally immunized with rHA plus an IL-1 family cytokine had significant protection against a lethal influenza virus infection. " 09/01/1990 - "donovani there was a significant reduction (P less than 0.001) in IL-1 levels on various post infection days irrespective whether Staph. " 06/01/1988 - "Despite the observed protective effects, animals treated with IL-1 did not have increased numbers of blood leukocytes or peritoneal phagocytes prior to infection or at the times coincident with bacterial clearance. " 08/01/2007 - "Our current results could provide a potential EORP-associated protection mechanism for bacteria infection by enhancing IL-1 expression and the clearance of contaminated LPS by macrophages." 03/15/2012 - "Consistent with the role for IL-1 signaling in infection clearance, mice deficient for the IL-1R antagonist cleared infection at a faster rate. "
4.	Neoplasms (Cancer) 01/01/1990 - "Exploitation of this increased IL-1 production by macrophages could be beneficial in the design of tumor treatment protocols." 05/01/1993 - "On the other hand, exogenous recombinant interleukin-1 was more effective in the enhancement of antitumor activity of the CD4+ T cells as compared with stimulant tumor cell administration. " 02/01/1991 - "From these findings, it appears that IL-1 enhances the cytotoxic effects of CY and X ray against tumors, an effect that would have considerable practical significance in the light of the protective effects shown elsewhere for the same lymphokine on normal tissues." 01/01/2006 - "Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment." 02/01/2003 - "Changes in several immunological parameters such as production of lymphocyte activating factor by peritoneal macrophages and the efficacy of those macrophages to kill tumor cell in vitro, responses of lymphocytes to mitogen, and weight and cellularity of spleen, respectively, correlated well with antimetastatic properties of the WSDP. "
5.	Arthritis (Polyarthritis) 03/01/1999 - "Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data." 11/01/2011 - "To assess the protective effects of the cytokine inhibitor interleukin-1 receptor antagonist (IL-1ra) on gene induction, an electroporation technique to treat adjuvant-induced arthritis (AIA) in rats was established, and its advantage was estimated in the present study. " 11/01/2007 - "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort." 01/01/2015 - "Interleukin-1 inhibitors were tested in large arthritis trials with less than impressive results, despite having convincing disease expression data and pre-clinical animal model supporting the potential pathogenic role of this cytokine in these settings. " 01/01/2012 - "The present study reveals two distinct subpopulations of arthritic mice with spontaneous arthritis due to deficiency for interleukin-1 receptor antagonist, suggesting that genes with function relevant to myeloid cell and/or apoptotic activities are most likely the key candidate genes for the QTL."

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
3.	Interleukin-6 (Interleukin 6)
4.	Cytokines
5.	Interleukin-10 (Interleukin 10)
6.	Interleukin-1beta (Interleukin 1 beta)
7.	Interleukin-1 (Interleukin 1)
8.	Interleukins
9.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
10.	Interleukin-1alpha (Interleukin 1 alpha)

Related Therapies and Procedures

1.	Injections
2.	Transplantation (Transplant Recipients)
3.	Drug Therapy (Chemotherapy)
4.	Intra-Articular Injections
5.	Transplants (Transplant)